ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.64 and traded as low as $2.02. ProQR Therapeutics shares last traded at $2.02, with a volume of 485,761 shares changing hands.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the company. StockNews.com cut ProQR Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, November 28th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday, January 10th. They set an "outperform" rating and a $15.00 target price for the company. Finally, Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $8.83.
View Our Latest Stock Report on ProQR Therapeutics
ProQR Therapeutics Price Performance
The stock has a market cap of $156.01 million, a PE ratio of -5.97 and a beta of 0.24. The firm has a 50 day moving average of $2.34 and a two-hundred day moving average of $2.63.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $30,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $39,000. Two Sigma Securities LLC acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $54,000. Institutional investors and hedge funds own 32.65% of the company's stock.
About ProQR Therapeutics
(
Get Free Report)
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Featured Articles
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
